{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-001663","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.427837+00:00","generated_at":"2026-05-28T09:11:07.711566+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CERo Therapeutics reports cash balance of ~$5.5M as of Jan 7, 2025 after warrant exercises and equity line sales","bullets":["Cash balance of approximately $5.463 million as of January 7, 2025.","Funds raised through warrant exercises for Series A Preferred Stock and sales under committed equity financing facility.","Filing updates prior 8-K on Dec 31, 2024; no other material changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-001663","json":"https://secwatch.observer/filing/0001213900-25-001663.json","markdown":"https://secwatch.observer/filing/0001213900-25-001663.md","text":"https://secwatch.observer/filing/0001213900-25-001663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025001663/0001213900-25-001663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025001663/ea0227074-8k_cerotherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:11:07.711566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}